American Journal of Cardiology
Volume 102, Issue 5 , Pages 530-534 , 1 September 2008

Drug-Eluting Stents Versus Bare Metal Stents for Narrowing in Saphenous Vein Grafts

Received 17 January 2008 ,Revised 23 April 2008 ,Accepted 23 April 2008.

References 

  1. Stephan WJ, O'Keefe JJH, Piehler JM, McCallister BD, Dahiya RS, Shumshak T, et al. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol. 1996;28:1140–1146
  2. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40:1951–1954
  3. Keeley EC, Velez CA, O'Neil WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous intervention on saphenous vein grafts. J Am Coll Cardiol. 2001;38:659–665
  4. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol. 1996;28:89–96
  5. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97:34–37
  6. Morice MC, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  8. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  9. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  10. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  11. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;107:517–520
  12. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  13. Tsuchida K, Ong ATL, Aoki J, van Mieghem CAG, Rodriguez-Granillo GA, Valgimigli M, et al Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol. 2005;96:395–398
  14. Vermeersch P, Agostoni P, Verheye S, van den Heurvel P, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol. 2006;48:2423–2431
  15. Vermeersch P, Agostoni P, Verheye S, van den Heurvel P, Convens C, van den Branden F, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol. 2007;50:261–267
  16. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989–994
  17. Bhargava B, Kornowski R, Mehran R, Kent KM, Hong MK, Lansky AJ, et al. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. J Am Coll Cardiol. 2000;35:389–397
  18. Mishra S, Wolfram RM, Torguson R, Chu WW, Xue Z, Gevorkian N, et al. Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis. Am J Cardiol. 2006;97:1303–1307
  19. Hong MK, Mehran R, Dangas G, Mints GS, Lansky AJ, Pichard AD, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100:2400–2405
  20. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol. 1999;33:88–96

PII: S0002-9149(08)00756-X

doi: 10.1016/j.amjcard.2008.04.041

American Journal of Cardiology
Volume 102, Issue 5 , Pages 530-534 , 1 September 2008

Article Tools

* Image Usage & Resolution